{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:43:02Z","timestamp":1792788182288,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nucleix","award":["Nucleix"],"award-info":[{"award-number":["Nucleix"]}],"id":[{"id":"https:\/\/ror.org\/0584knp84","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08249-0","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:16:06Z","timestamp":1779110166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Role of Bladder EpiCheck\u00ae in Bladder cancer: from primary diagnosis to surveillance"],"prefix":"10.1186","volume":"24","author":[{"given":"Marcel","family":"Figueras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"Ingelmo-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella L.","family":"Roldan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Gom\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Galve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e0udia","family":"Mercader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Llu\u00eds","family":"Peri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Asiain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Alcaraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-9422","authenticated-orcid":false,"given":"Lourdes","family":"Mengual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"8249_CR1","doi-asserted-by":"crossref","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F et al. European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and Carcinoma In Situ)\u2014a summary of the 2024 guidelines update. Eur Urol. 2024.","DOI":"10.1016\/j.eururo.2024.07.027"},{"key":"8249_CR2","doi-asserted-by":"publisher","first-page":"e6625","DOI":"10.1016\/j.urolonc.2014.06.008","volume":"33","author":"F Yafi","year":"2015","unstructured":"Yafi F FA, Brimo, Steinberg J, Aprikian AG, Tanguay S, Kassouf W. Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer. Urologic Oncology: Seminars Original Investigations. 2015;33:66.e6625\u201331.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"8249_CR3","doi-asserted-by":"crossref","unstructured":"Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths T et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol Assess (Rockv). 2010;14.","DOI":"10.3310\/hta14040"},{"key":"8249_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/S0266462310001364","volume":"27","author":"G Mowatt","year":"2011","unstructured":"Mowatt G, N\u2019Dow J, Vale L, Nabi G, Boachie C, Cook JA, et al. Photodynamic diagnosis of bladder cancer compared with white light cystoscopy: Systematic review and meta-analysis. Int J Technol Assess Health Care. 2011;27:3\u201310.","journal-title":"Int J Technol Assess Health Care"},{"key":"8249_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/bju.14574","volume":"124","author":"Y Freifeld","year":"2019","unstructured":"Freifeld Y, Lotan Y. Effect of blue-light cystoscopy on contemporary performance of urine cytology. BJU Int. 2019;124:251\u20137. https:\/\/doi.org\/10.1111\/bju.14574.","journal-title":"BJU Int"},{"key":"8249_CR6","unstructured":"Reid MD, Osunkoya AO, Siddiqui MT, Looney SW. Accuracy of grading of urothelial carcinoma on urine cytology: an analysis of interobserver and intraobserver agreement. Int J Clin Exp Pathol. 2012;5:882\u201391. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC3484494\/."},{"key":"8249_CR7","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","volume":"4","author":"E Laukhtina","year":"2021","unstructured":"Laukhtina E, Shim SR, Mori K, D\u2018Andrea D, Soria F, Rajwa P, et al. Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2021;4:927\u201342.","journal-title":"Eur Urol Oncol"},{"key":"8249_CR8","doi-asserted-by":"crossref","unstructured":"Pierconti F, Martini M, Cenci T, Fiorentino V, Gianfrancesco L, Di, Ragonese M et al. The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma. Urologic Oncology: Seminars and Original Investigations. 2022;40:108.e19-108.e25.","DOI":"10.1016\/j.urolonc.2021.11.013"},{"key":"8249_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","volume":"1","author":"JA Witjes","year":"2018","unstructured":"Witjes JA, Morote J, Cornel EB, Gakis G, van Valenberg FJP, Lozano F, et al. Performance of the Bladder EpiCheckTM Methylation Test for Patients Under Surveillance for Non\u2013muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial. Eur Urol Oncol. 2018;1:307\u201313.","journal-title":"Eur Urol Oncol"},{"key":"8249_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1111\/bju.14673","volume":"123","author":"D D\u2019Andrea","year":"2019","unstructured":"D\u2019Andrea D, Soria F, Zehetmayer S, Gust KM, Korn S, Witjes JA, et al. Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non\u2010muscle\u2010invasive bladder cancer. BJU Int. 2019;123:959\u201367.","journal-title":"BJU Int"},{"key":"8249_CR11","doi-asserted-by":"publisher","unstructured":"Artero Fullana S, Ca\u00f1o Velasco J, Lafuente Puentedura A, Polanco Pujol L, Bataller Monfort V, Moralejo G\u00e1rate M, et al. Diagnostic accuracy of Bladder EpiCheck for upper tract urothelial carcinoma: a meta-analysis. Actas Urol Esp (Engl Ed). 2025;49:501720. https:\/\/doi.org\/10.1016\/j.acuroe.2025.501720.","DOI":"10.1016\/j.acuroe.2025.501720"},{"key":"8249_CR12","doi-asserted-by":"crossref","unstructured":"Palermo M, D\u2019elia C, Trenti E, Mian Comploje, Schwienbacher C. C, Prospective evaluation of the RT-PCR based urinary marker Bladder Epicheck\u00ae as a diagnostic tool in upper urinary tract tumor. Minerva Urol Nephrol. 2024;76.","DOI":"10.23736\/S2724-6051.23.05488-5"},{"key":"8249_CR13","unstructured":"Rold\u00e1n FL, Ingelmo-Torres M, Mercader C, Figueras M, Padull\u00e9s B, Dur\u00e1n MA et al. Bladder scp EpiCheck clinical utility to predict BCG response in non\u2010muscle\u2010invasive bladder cancer. BJU Int. 2025."},{"key":"8249_CR14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodr\u00edguez O, Hern\u00e1ndez V, Turturica D, Bauerov\u00e1 L, Bruins HM, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non\u2013muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79:480\u20138.","journal-title":"Eur Urol"},{"key":"8249_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.acuro.2019.03.011","volume":"43","author":"W Krajewski","year":"2019","unstructured":"Krajewski W, Rodr\u00edguez-Faba O, Breda A, Pisano F, Poletajew S, Tukiendorf A, et al. Los sistemas de clasificaci\u00f3n de la OMS de 1973 y 2004 difieren en la predicci\u00f3n de supervivencia entre los pacientes con c\u00e1ncer de vejiga en estadio T1. Actas Urol Esp. 2019;43:467\u201373.","journal-title":"Actas Urol Esp"},{"key":"8249_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000446270","volume":"60","author":"GA Barkan","year":"2016","unstructured":"Barkan GA, Wojcik EM, Nayar R, Savic-Prince S, Quek ML, Kurtycz DFI, et al. The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. Acta Cytol. 2016;60:185\u201397.","journal-title":"Acta Cytol"},{"key":"8249_CR17","doi-asserted-by":"crossref","unstructured":"Wasserstrom A, Frumkin D, Dotan Z, Bukin E, Gadish T, Hanuka S et al. MP13-15 MOLECULAR URINE CYTOLOGY \u2013 BLADDER EPICHECK IS A NOVEL MOLECULAR DIAGNOSTIC TOOL FOR MONITORING OF BLADDER CANCER PATIENTS. J Urol. 2016;195.","DOI":"10.1016\/j.juro.2016.02.2496"},{"key":"8249_CR18","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/23523735241304348","volume":"10","author":"N Fleshner","year":"2024","unstructured":"Fleshner N, Grossman HB, Berglund R, Hafron J, Inman B, Karsh L, et al. North American study and meta-analysis evaluating performance of Bladder EpiCheck \u00ae, a FDA cleared test, in non-muscle invasive bladder cancer recurrence. Bladder Cancer. 2024;10:278\u201389.","journal-title":"Bladder Cancer"},{"key":"8249_CR19","doi-asserted-by":"crossref","unstructured":"Mariappan P, Hart-Brooke J, Sparks R, Lord-McKenzie T. Bladder EpiCheck triggered photodynamic diagnosis biopsies detect high-grade bladder cancer recurrences missed by white light cystoscopy. Eur Urol Oncol. 2025.","DOI":"10.1016\/j.eururo.2025.09.3865"},{"key":"8249_CR20","doi-asserted-by":"publisher","first-page":"12489","DOI":"10.3390\/ijms241512489","volume":"24","author":"V Fiorentino","year":"2023","unstructured":"Fiorentino V, Pizzimenti C, Franchina M, Rossi ED, Tralongo P, Carlino A, et al. Bladder Epicheck Test: A Novel Tool to Support Urothelial Carcinoma Diagnosis in Urine Samples. Int J Mol Sci. 2023;24:12489.","journal-title":"Int J Mol Sci"},{"key":"8249_CR21","volume-title":"EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS)","author":"P Gontero","year":"2025","unstructured":"Gontero P, Birtle A, Comp\u00e9rat E, Dominguez Escrig JL, Liedberg F, Mariappan P, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). Arnhem, The Netherlands: EAU Guidelines Office; 2025."},{"key":"8249_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/cncy.22152","volume":"127","author":"E Trenti","year":"2019","unstructured":"Trenti E, D\u2019Elia C, Mian C, Schwienbacher C, Hanspeter E, Pycha A, et al. Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non\u2013muscle\u2010invasive bladder cancer. Cancer Cytopathol. 2019;127:465\u20139.","journal-title":"Cancer Cytopathol"},{"key":"8249_CR23","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.3390\/ijms21186542","volume":"21","author":"M Mancini","year":"2020","unstructured":"Mancini M, Righetto M, Zumerle S, Montopoli M, Zattoni F. The Bladder EpiCheck Test as a Non-Invasive Tool Based on the Identification of DNA Methylation in Bladder Cancer Cells in the Urine: A Review of Published Evidence. Int J Mol Sci. 2020;21:6542.","journal-title":"Int J Mol Sci"},{"key":"8249_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.euo.2025.04.020","volume":"8","author":"BJ Schmitz-Dr\u00e4ger","year":"2025","unstructured":"Schmitz-Dr\u00e4ger BJ, Bismarck E, Roghmann F, von Landenberg N, Noldus J, Jahn D, et al. Results of the Prospective Randomized UroFollow Trial Comparing Marker-guided Versus Cystoscopy-based Surveillance in Patients with Low\/Intermediate-risk Bladder Cancer. Eur Urol Oncol. 2025;8:1041\u20139.","journal-title":"Eur Urol Oncol"},{"key":"8249_CR25","doi-asserted-by":"crossref","unstructured":"Ca\u00f1o Velasco J, Artero Fullana S, Polanco Pujol L, Lafuente Puentedura A, Subiela JD, Arag\u00f3n Chamizo J et al. Use of Bladder Epicheck\u00ae in the follow-up of non-muscle-invasive Bladder cancer: a systematic literature review. Actas Urol\u00f3gicas Espa\u00f1olas (English Edition). 2024.","DOI":"10.1016\/j.acuroe.2024.05.004"},{"key":"8249_CR26","doi-asserted-by":"publisher","first-page":"e947","DOI":"10.1016\/S1569-9056(19)30689-X","volume":"18","author":"F Lozano Palacio","year":"2019","unstructured":"Lozano Palacio F, Morote J, Leibovitch I, Cornel EB, Joyce J, Gakis G, et al. Performance of bladder EpiCheckTM for NMIBC monitoring - updated results of a European multi-center study. Eur Urol Supplements. 2019;18:e947\u20139.","journal-title":"Eur Urol Supplements"},{"key":"8249_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ucl.2022.09.009","volume":"50","author":"Y Lotan","year":"2023","unstructured":"Lotan Y, Baky FJ. Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non\u2013muscle-Invasive Bladder Cancer. Urol Clin North Am. 2023;50:53\u201367.","journal-title":"Urol Clin North Am"},{"key":"8249_CR28","doi-asserted-by":"publisher","first-page":"e6513","DOI":"10.1016\/j.urolonc.2025.10.008","volume":"44","author":"Savage","year":"2026","unstructured":"Savage SJ, Ercole CE, Hemstreet G, Leone A, Masterson T, McWilliams G, et al. Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study. Urologic Oncology: Seminars Original Investigations. 2026;44:e6513\u201320.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"8249_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1186\/s12935-021-02169-3","volume":"21","author":"D Shang","year":"2021","unstructured":"Shang D, Liu Y, Xu X, Chen Z, Wang D. Diagnostic value comparison of CellDetect, fluorescent in situ hybridization (FISH), and cytology in urothelial carcinoma. Cancer Cell Int. 2021;21:465.","journal-title":"Cancer Cell Int"},{"key":"8249_CR30","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.acuroe.2023.06.011","volume":"47","author":"J Ca\u00f1o Velasco","year":"2023","unstructured":"Ca\u00f1o Velasco J, Polanco Pujol L, Moreno Cort\u00e9s JC, Lafuente Puentedura A, Hern\u00e1ndez Fern\u00e1ndez C. Bladder Epicheck\u00ae for surveillance in high-risk non-muscle-invasive bladder cancer: Initial experience and follow-up proposal. Actas Urol\u00f3gicas Espa\u00f1olas (English Edition). 2023;47:471\u20133.","journal-title":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"},{"key":"8249_CR31","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cncy.22246","volume":"128","author":"E Trenti","year":"2020","unstructured":"Trenti E, Pycha S, Mian C, Schwienbacher C, Hanspeter E, Kafka M, et al. Comparison of 2 new real-time polymerase chain reaction\u2013based urinary markers in the follow\u2010up of patients with non\u2013muscle\u2010invasive bladder cancer. Cancer Cytopathol. 2020;128:341\u20137.","journal-title":"Cancer Cytopathol"},{"key":"8249_CR32","doi-asserted-by":"crossref","unstructured":"Cochetti G, Rossi de Vermandois JA, Maul\u00e0 V, Cari L, Cagnani R, Suvieri C et al. Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: a single centre, prospective, blinded clinical trial. Urologic Oncology: Seminars and Original Investigations. 2022;40:105.e11-105.e18.","DOI":"10.1016\/j.urolonc.2021.11.001"},{"key":"8249_CR33","doi-asserted-by":"publisher","first-page":"e3118","DOI":"10.1016\/S1569-9056(19)33362-7","volume":"18","author":"ML Righetto","year":"2019","unstructured":"Righetto ML, Zumerle S, Barcaro F, Saponaio M, Montopoli M, Ragazzi E, et al. Genomic subtypes of bladder cancer with distinct methylation profiles could be better identified by the Bladder EpiCheck test as compared to cystoscopy\/urine cytology. Eur Urol Supplements. 2019;18:e3118.","journal-title":"Eur Urol Supplements"},{"key":"8249_CR34","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.3390\/jcm11133855","volume":"11","author":"KB Pe\u00f1a","year":"2022","unstructured":"Pe\u00f1a KB, Riu F, Hernandez A, Guilarte C, Badia J, Parada D. Usefulness of the Urine Methylation Test (Bladder EpiCheck\u00ae) in Follow-Up Patients with Non-Muscle Invasive Bladder Cancer and Cytological Diagnosis of Atypical Urothelial Cells\u2014An Institutional Study. J Clin Med. 2022;11:3855.","journal-title":"J Clin Med"},{"key":"8249_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.eururo.2025.03.018","volume":"88","author":"T Dreyer","year":"2025","unstructured":"Dreyer T, Brandt S, Fabrin K, Azawi N, V\u00e1squez JL, Ernst A, et al. Use of the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade Non\u2013muscle-invasive Bladder Cancer: Results from the Randomized Controlled DaBlaCa-15 Trial. Eur Urol. 2025;88:23\u201330.","journal-title":"Eur Urol"},{"key":"8249_CR36","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/bju.15418","volume":"128","author":"B Cowan","year":"2021","unstructured":"Cowan B, Klein E, Jansz K, Westenfelder K, Bradford T, Peterson C, et al. Longitudinal follow-up and performance validation of an mRNA\u2010based urine test (Xpert \u00ae Bladder Cancer Monitor) for surveillance in patients with non\u2010muscle\u2010invasive bladder cancer. BJU Int. 2021;128:713\u201321.","journal-title":"BJU Int"},{"key":"8249_CR37","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.euo.2020.12.002","volume":"4","author":"BWG van Rhijn","year":"2021","unstructured":"van Rhijn BWG, Hentschel AE, Br\u00fcndl J, Comp\u00e9rat EM, Hern\u00e1ndez V, \u010capoun O, et al. Prognostic Value of the WHO1973 and WHO2004\/2016 Classification Systems for Grade in Primary Ta\/T1 Non\u2013muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non\u2013muscle-invasive Bladder Cancer Guidelines Panel Study. Eur Urol Oncol. 2021;4:182\u201391.","journal-title":"Eur Urol Oncol"},{"key":"8249_CR38","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BWG van Rhijn","year":"2009","unstructured":"van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and Progression of Disease in Non\u2013Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. Eur Urol. 2009;56:430\u201342.","journal-title":"Eur Urol"},{"key":"8249_CR39","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pi\u00f1eiro L, Gonzalez M, et al. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol. 2009;182:2195\u2013203.","journal-title":"J Urol"},{"key":"8249_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/cncy.22657","volume":"131","author":"F Pierconti","year":"2023","unstructured":"Pierconti F, Rossi ED, Cenci T, Carlino A, Fiorentino V, Totaro A, et al. DNA methylation analysis in urinary samples: A useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group. Cancer Cytopathol. 2023;131:158\u201364.","journal-title":"Cancer Cytopathol"},{"key":"8249_CR41","doi-asserted-by":"publisher","first-page":"e13117","DOI":"10.1016\/j.urolonc.2020.06.018","volume":"39","author":"F Pierconti","year":"2021","unstructured":"Pierconti F, Martini M, Fiorentino V, Cenci T, Capodimonti S, Straccia P, et al. The combination cytology\/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence? Urologic Oncology: Seminars Original Investigations. 2021;39:e13117\u201321.","journal-title":"Urologic Oncology: Seminars Original Investigations"},{"key":"8249_CR42","first-page":"2473","volume":"60","author":"C Salem","year":"2000","unstructured":"Salem C, Liang G, Tsai YC, Coulter J, Knowles MA, Feng AC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res. 2000;60:2473\u20136.","journal-title":"Cancer Res"},{"key":"8249_CR43","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","volume":"23","author":"JWF Catto","year":"2005","unstructured":"Catto JWF, Azzouzi A-R, Rehman I, Feeley KM, Cross SS, Amira N, et al. Promoter Hypermethylation Is Associated With Tumor Location, Stage, and Subsequent Progression in Transitional Cell Carcinoma. J Clin Oncol. 2005;23:2903\u201310.","journal-title":"J Clin Oncol"},{"key":"8249_CR44","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.urolonc.2020.08.016","volume":"39","author":"K Ng","year":"2021","unstructured":"Ng K, Stenzl A, Sharma A, Vasdev N. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions. Urologic Oncology: Seminars Original Investigations. 2021;39:41\u201351.","journal-title":"Urologic Oncology: Seminars Original Investigations"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08249-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08249-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:03:03Z","timestamp":1790107383000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08249-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8249"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08249-0","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article updated to correct the grant number in funding section.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All methods were carried out in accordance with relevant guidelines and regulations. All participants provided written informed consent (HCB\/2013\/8753) before being included in this study. The study methodologies conformed to the standards set by Declaration of Helsinki and were approved by the Clinical Research Ethics Committee of the Hospital Clinic of Barcelona (HCB\/2018\/0746; HCB2021\/1168; HCB\/2022\/0557).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lourdes Mengual certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (e.g., employment\/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: L. Mengual is a consultant for Nucleix. A. Antonio Alcaraz has received honorarium as speaker or part of advisory boards from the following companies: Astellas, Janssen, Ipsen, Bayer, Sanofi, Olympus and Intuitive Surgical. The remaining authors have nothing to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"889"}}